Peptides in Montréal: Research Cluster, Tax and Language

Montréal has the deepest concentration of pharmaceutical and clinical research institutes of any city in this series, and it also has the highest combined sales tax rate in the set and the only non-tax provincial obligation in the country. This page is about those three things. It is not a transit page — Montréal is one day from Vancouver on Canada Post Priority, the same as Toronto, Winnipeg and Calgary, and there is nothing distinctive to say about the route.

Nine institutions, and why the exact names matter

What follows is a description of a city, not a client list. Nothing named here is a customer, partner or affiliate of ThePeptide, and we would not imply otherwise. Every name was checked against the institution's own site in August 2026.

Naming precision is not pedantry on this page in particular. Half of these institutions have an official name in French, some have an official bilingual name in which both halves are part of the name, and the province has statutory expectations about language that make getting them right the same argument in miniature. A supplier that writes “Montreal Clinical Research Institute” alone, or drops the accents, is telling you something about how carefully it handles the rest of its documentation.

One boundary before the list. This page covers Montréal and the province-level picture — the institutional cluster, the QST rate and the labelling obligation. Québec City is a separate market with a separate logistics story and has its own page on transit timing and the Charter's website rule. Earlier versions of both pages chased the same province-wide search term and said much the same thing twice; they no longer do.

The francophone axis

The Université de Montréal side of the city carries its density through the Faculté de pharmacie and Faculté de médecine, with the Centre de recherche du CHUM (CRCHUM) as the affiliated hospital research centre. The Institut de recherches cliniques de Montréal (IRCM) / Montreal Clinical Research Institute is a separate body with a long record in molecular biology, immunology and metabolic disease; the bilingual construction with the slash is its official name, not a translation convenience. Polytechnique Montréal and CHU Sainte-Justine also appeared in earlier versions of this page — both are real, both are Montréal institutions, and both were carried over from older site copy without independent verification in the research file behind this rebuild, so they are named here with that caveat attached rather than presented on the same footing as the rest.

The McGill axis

The Neuro (Montreal Neurological Institute-Hospital) is a McGill institute and hospital in one entity, and the hyphenated form is the official one. The Rosalind and Morris Goodman Cancer Institute took its current name when the former Goodman Cancer Research Centre was re-established as an institute; older pages across the web still use the “Research Centre” form. The Research Institute of the McGill University Health Centre (RI-MUHC) is the health centre's research arm, and the Lady Davis Institute at the Jewish General Hospital is the fourth of the McGill-affiliated research bodies in the city.

Where a specialty concentrates

The Montreal Heart Institute / Institut de Cardiologie de Montréal is the clearest example of a single-specialty concentration in the set: a hospital and research centre built around cardiovascular work, with an official name that is bilingual in the same way the IRCM's is. Outside the island, at Laval, the INRS – Centre Armand-Frappier Santé Biotechnologie is the health-and-biotechnology centre of the Institut national de la recherche scientifique. That centre has been renamed more than once — it was the INRS-Institut Armand-Frappier for years — and the current form is the one above; older site copy used the earlier version.

What a list like this is for, and what it is not: it is a description of where peptide-adjacent work physically sits in one city, so that a reader can judge whether the surrounding environment is one where lot-level documentation is ordinary or exceptional. It is not a customer list, a referral network or a claim of association, and no page on this site will present it as one. The reason it is worth publishing at all is that it is checkable — every entry above has a public site you can open, which is more than can be said for the aggregate statistics it replaced.

The statistic we took off this page

Previous versions of this page said that Greater Montréal generates approximately 50 per cent of all pharmaceutical R&D investment in Canada, and said it twice, in two adjacent sections, one of which existed only to repeat it. Alongside it sat “over 680 life sciences companies” and “over 32,000 people.”

None of those three figures is stated on this page now. They were carried in existing site copy without a citation, and when we went looking for the original source in August 2026 we could not attach any of them to a current published statement. That does not make them false; it makes them unsourced, and an unsourced round number in a competitive claim is precisely the kind of thing this rebuild is removing. The verifiable version of the same point is the list of named institutions above, each of which you can open and check yourself. That is a weaker headline and a stronger claim.

14.975 per cent, and what it is not

An order to a Montréal address is taxed at 5 per cent GST plus 9.975 per cent QST, a combined 14.975 per cent — the highest total of any city in this series, and 9.975 percentage points above an Alberta address, where only the federal 5 per cent applies. Unlike Nova Scotia's harmonized 14 per cent, this is genuinely two taxes: a federal one and a provincial one, applied together.

What we will not do is turn that into a worked landed-cost example. Whether a specific item is taxable, and at which rate, is a separate question from what the statutory rate is, and it is not one we are going to answer with an illustrative number on a city page. The rate is the fact; your invoice is the arithmetic.

Labelling into Quebec: the June 2025 rule

Quebec's Charter of the French Language is the only genuine non-tax provincial variation affecting a supplier anywhere in this series. Two distinct obligations sit inside it, and they are frequently run together. The one about websites and being served in French is set out on our Québec City page, which covers transit timing and the French-language obligations. The one that belongs here is about the physical product.

Since 1 June 2025, no language other than French may be given greater prominence in the packaging and labelling of products sold in Quebec, and that prominence rule now extends to generic terms and product descriptions rather than stopping at trademarks. The underlying prominence requirement is not new — it has existed in some form since 1977 — but the extension to generic and descriptive wording is. A transitional allowance runs to 1 June 2027 for products manufactured before 1 June 2025 where no French version of the product's recognised trademark was registered as of 26 June 2024; it applies to the new generic-and-descriptive requirement, not to the older prominence rule. Verified against a McCarthy Tétrault analysis dated 26 May 2025, as of August 2026.

This is an operational obligation on the seller, not a restriction on the buyer, and it attaches to what physically arrives at a Quebec address. We are naming it here because a supplier shipping labelled product into Quebec is inside its scope whether or not it has a Quebec address, and because most pages in this industry mention Bill 96 without ever saying what it actually requires.

Beyond tax and language, there is no Quebec rulebook

Everything else governing these compounds is federal and identical across the country: the Food and Drugs Act, the Controlled Drugs and Substances Act where applicable, Health Canada, and the Canada Border Services Agency at the frontier. There is no Quebec licensing scheme, no provincial registry and no provincial classification for research chemicals of this kind. Saying that plainly is more useful than inventing a provincial regime, and it is the reason the detailed treatment lives in one place, on our Ottawa page on the federal regulatory framework, rather than being restated with a provincial gloss on thirteen pages.

Ordering into Montréal from British Columbia

Orders leave New Westminster, British Columbia. There is no Montréal facility, no Quebec address and no pickup counter anywhere in the country. The commitment is identical for every Canadian address: free shipping with no minimum order value, tracking on every parcel, dispatch within 48 hours Monday to Friday, 2–8 business days typical delivery, in discreet, unbranded, tamper-evident, temperature-stable packaging. Quebec runs on Eastern Time, three hours ahead of the origin all year.

Canada Post's October 2025 Delivery Standards list Montréal at 1 day from a Vancouver origin on Priority, its air product — the same as Toronto, Ottawa and Calgary, and one day faster than the listing for Québec. Verified as of August 2026. That is a Priority figure from a Priority table: not Expedited, not Regular Parcel, and not the service your order travels on. Every lot we ship into Quebec carries the same documentation as every other, published against its lot number before the lot goes on sale — Semaglutide 10 mg and Ipamorelin 10 mg among them — and our guide to reading a peptide Certificate of Analysis explains what to look at first.

Neighbouring pages: Québec City covers the dispatch-window arithmetic for a two-day destination, Toronto and the GTA covers institutional procurement, and Halifax covers the Atlantic route and marine-air storage.

Regulatory status and research-use position

On 9 April 2026, Health Canada published a public advisory, “Think twice before injecting peptides bought online: unauthorized products can seriously harm you,” naming retatrutide, BPC-157, CJC-1295, GHK-Cu, MOTS-C, TB-500 and other compounds. The advisory states that peptides of this kind are generally regulated as prescription drugs in Canada, that unauthorized drug products are illegal, and — addressing the labelling convention this industry relies on directly — that this type of labelling does not make these products legal or exempt from regulatory requirements. On 11 June 2026 the Superior Court of Québec granted Health Canada a permanent injunction against a Canadian seller of injectable peptides; Health Canada announced it publicly on 29 July 2026. Enforcement is active.

Our position is unambiguous. ThePeptide supplies these compounds as laboratory research materials only. They are not approved by Health Canada for human or veterinary use, and they are not sold for those purposes. We make no therapeutic claims. We publish no dosing, administration, injection, or preparation guidance of any kind, and we do not provide it on request. Nothing on this site tells anyone how to use these compounds in a person, because they are not supplied for that purpose. Nothing we supply is intended for human consumption, injection, veterinary use, diagnostic use, cosmetic use, or therapeutic application.

If you are considering these compounds for personal health reasons, the advisory is addressed to you and you should read it before going further: Health Canada public advisory, 9 April 2026. Speak to a licensed healthcare practitioner.

What we do commit to, for the laboratory-research market we serve: every lot is independently tested by HPLC‑UV for purity and by mass spectrometry for identity, and the batch-specific Certificate of Analysis is published before the lot goes on sale, with the lot number printed on the vial.

Montréal questions

Why is there no longer a figure on this page for Montréal's share of Canadian pharmaceutical research spending?

Because we could not source it. The claim was that Greater Montréal generates roughly 50 per cent of all Canadian pharmaceutical research and development investment, and the previous version made it twice, in two adjacent sections. When we looked in August 2026 for a current published statement behind it — along with the “680 life sciences companies” and “32,000 people” figures beside it — we could not attach any of the three to one. They are not necessarily wrong; they are unsourced, and the named, checkable institution list replaces them.

Does Quebec's June 2025 product-labelling rule apply to a vial shipped from British Columbia?

It attaches to products sold in Quebec, so an out-of-province seller shipping labelled product to a Quebec address is inside its scope. Since 1 June 2025 no language other than French may be given greater prominence in packaging and labelling, now extended to generic terms and product descriptions. A transitional allowance runs to 1 June 2027 for product manufactured before 1 June 2025 where no French version of the recognised trademark was registered as of 26 June 2024.

Why is an order to a Montréal address taxed at 14.975%?

Because Quebec applies 9.975% QST on top of the 5% federal GST, which combines to 14.975% — the highest total in this series and 9.975 points above an Alberta address. Unlike a harmonized province, those are two separate taxes rather than one blended rate. Whether a particular item is taxable is a separate question from the rate, and not one we answer with a worked example.

Why does this page write institution names in both French and English?

Because for several of them the bilingual form is the official name rather than a translation. The Institut de recherches cliniques de Montréal (IRCM) / Montreal Clinical Research Institute and the Montreal Heart Institute / Institut de Cardiologie de Montréal are the clearest cases. Others have a single official form that is easy to get wrong, such as The Neuro (Montreal Neurological Institute-Hospital) with its hyphen.

Montréal is one day on Canada Post Priority and Québec City is two. Does my Montréal order arrive sooner?

Possibly, but that is not what those numbers say. They are Canada Post's Priority (air) standards from its October 2025 table, and Priority is not the service your order travels on. Our commitment is the same to both addresses: dispatch within 48 hours Monday to Friday and 2 to 8 business days typical delivery. The Priority figures are useful as a comparison between destinations, not as a delivery date.